全文获取类型
收费全文 | 1753492篇 |
免费 | 132217篇 |
国内免费 | 8548篇 |
专业分类
耳鼻咽喉 | 22307篇 |
儿科学 | 56276篇 |
妇产科学 | 46728篇 |
基础医学 | 248456篇 |
口腔科学 | 49770篇 |
临床医学 | 159455篇 |
内科学 | 342103篇 |
皮肤病学 | 39197篇 |
神经病学 | 134489篇 |
特种医学 | 66288篇 |
外国民族医学 | 276篇 |
外科学 | 263614篇 |
综合类 | 49870篇 |
现状与发展 | 20篇 |
一般理论 | 532篇 |
预防医学 | 128315篇 |
眼科学 | 41981篇 |
药学 | 130151篇 |
60篇 | |
中国医学 | 7781篇 |
肿瘤学 | 106588篇 |
出版年
2021年 | 16120篇 |
2019年 | 15646篇 |
2018年 | 22178篇 |
2017年 | 17193篇 |
2016年 | 18491篇 |
2015年 | 21951篇 |
2014年 | 29843篇 |
2013年 | 41015篇 |
2012年 | 57515篇 |
2011年 | 60693篇 |
2010年 | 36182篇 |
2009年 | 33206篇 |
2008年 | 54672篇 |
2007年 | 58105篇 |
2006年 | 58479篇 |
2005年 | 55902篇 |
2004年 | 52852篇 |
2003年 | 50171篇 |
2002年 | 48072篇 |
2001年 | 93010篇 |
2000年 | 94998篇 |
1999年 | 78429篇 |
1998年 | 20733篇 |
1997年 | 18222篇 |
1996年 | 18119篇 |
1995年 | 17431篇 |
1994年 | 15943篇 |
1993年 | 14450篇 |
1992年 | 57786篇 |
1991年 | 55625篇 |
1990年 | 53274篇 |
1989年 | 51022篇 |
1988年 | 46330篇 |
1987年 | 45126篇 |
1986年 | 42358篇 |
1985年 | 40078篇 |
1984年 | 29403篇 |
1983年 | 24949篇 |
1982年 | 13934篇 |
1979年 | 25548篇 |
1978年 | 17576篇 |
1977年 | 14908篇 |
1976年 | 13874篇 |
1975年 | 14565篇 |
1974年 | 17630篇 |
1973年 | 16945篇 |
1972年 | 15673篇 |
1971年 | 14453篇 |
1970年 | 13431篇 |
1969年 | 12517篇 |
排序方式: 共有10000条查询结果,搜索用时 328 毫秒
11.
12.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
13.
14.
Bortezomib is a novel proteasome inhibitor, which has been successfully used to treat mantle cell lymphoma and multiple myeloma. However, the direct effects of bortezomib on acute promyelocytic leukaemia (APL) have not been fully investigated. In the present study, the WST-8 assay, western blotting, flow cytometry, monodansylcadaverine staining and transmission electron microscopy were performed. It was demonstrated that bortezomib treatment induced a time- and dose-dependent decrease in the viability of NB4 cells. Bortezomib treatment induced cell apoptosis in NB4 cells, as assessed by Annexin V/propidium iodide analysis, and the detection of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, Bax and Bcl-2 expression. Furthermore, bortezomib treatment induced autophagy in NB4 cells, as indicated by autophagosome formation, p62 degradation, LC3-I to LC3-II conversion and formation of acidic autophagic vacuoles. Notably, autophagy induced by bortezomib was initiated prior to apoptosis. Inhibition of autophagy by knocking down Beclin-1 expression increased bortezomib-induced apoptosis in NB4 cells. Therefore, the present study revealed that the combination of bortezomib and autophagy inhibition may be a potential treatment strategy for APL. 相似文献
15.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
16.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
17.
18.
Clinical & Experimental Metastasis - 相似文献
19.
20.